Stockscreener 앱 받기
357.13
1.86%
6.53
시간 외 거래:
357.13
전일 마감가:
$350.60
열려 있는:
$346.29
하루 거래량:
304.31K
Relative Volume:
0.77
시가총액:
$9.96B
수익:
$7.46M
순이익/손실:
$-303.27M
주가수익비율:
-26.52
EPS:
-13.4668
순현금흐름:
$-249.12M
1주 성능:
+6.41%
1개월 성능:
+7.90%
6개월 성능:
+89.42%
1년 성능:
+889.28%
1일 변동 폭
$346.29
$366.52
1주일 범위
$329.96
$366.52
52주 변동 폭
$35.21
$366.52
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
357.13 | 9.77B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
437.27 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
627.74 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
820.51 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.64 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.00 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Strong Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-02 | 개시 | Wells Fargo | Equal Weight |
| 2025-12-15 | 재확인 | Oppenheimer | Outperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis Precision Medicines stock hits 52-week high at 360.8 USD - Investing.com
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,245 - Moomoo
PRAX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $1245 - GuruFocus
H.C. Wainwright reiterates Praxis Precision stock rating on patent news By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Praxis Precision stock rating on patent news - Investing.com
PRAX Reiterated by BTIG -- Price Target Maintained at $843.00 - GuruFocus
Praxis (NASDAQ: PRAX) counsel adds 78 ESPP shares, holds 26,010.667 - Stock Titan
Praxis (NASDAQ: PRAX) accounting officer adds shares through employee stock purchase plan - Stock Titan
Praxis (PRAX) CEO acquires 126 ESPP shares as compensation - Stock Titan
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN
HighVista Strategies Sells 69,092 Shares of Structure Therapeutics in Q1 2026News and Statistics - IndexBox
Is FDA NDA Progress Amid Wider Losses Altering The Investment Case For Praxis Precision Medicines (PRAX)? - Yahoo Finance
Needham Reiterates Praxis Precision Medicines (PRAX) Buy Recommendation - MSN
(PRAX) Volatility Zones as Tactical Triggers - Stock Traders Daily
[SCHEDULE 13G] Praxis Precision Medicines, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Point72 entities and Cohen report 0.2% stake in Praxis (PRAX) - Stock Titan
Orbis and Allan Gray report 8.9% stake in Praxis Precision Medicines (PRAX) - Stock Titan
Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - MSN
Praxis Precision Medicines stock (US74006W1036): Biotech innovator in CNS disorders - AD HOC NEWS
Praxis Precision Medicines stock hits 52-week high at $358.01 By Investing.com - Investing.com South Africa
Praxis Highlights FDA NDA Acceptances and Strengthened Cash Runway - TipRanks
Praxis (PRAX) widens Q1 2026 loss while advancing four late-stage CNS drugs - Stock Titan
Praxis Precision Medicines stock hits 52-week high at $358.01 - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Given New $715.00 Price Target at Truist Financial - MarketBeat
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $715 - Moomoo
HC Wainwright Issues Pessimistic Outlook for PRAX Earnings - MarketBeat
Lifesci Capital Brokers Lower Earnings Estimates for PRAX - MarketBeat
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Praxis Precision Medicines Maps High-Stakes Launch Path - TipRanks
Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX) - Yahoo Finance
UBS Group AG Sells 7,612 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen - Insider Monkey
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $795 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $166 to $1,245 - Moomoo
Number of shareholders of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis Precision Medicines Q1 Earnings Call Highlights - TradingView
Praxis Precision Medicines, Inc.Common Stock (Nasdaq:PRAX) Stock Quote - FinancialContent
PRAX Maintained by Wedbush -- Price Target Raised to $166.00 - GuruFocus
Deutsche Bank Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $420 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,245 - Moomoo
Praxis Precision Medicines, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $420 From $444, Maintains Buy Rating - marketscreener.com
PRAX Reiterated by BTIG -- Price Target Maintained at $843 - GuruFocus
Praxis Precision Medicines, Inc (PRAX): Investor Outlook on a Biotechnology Challenger with 90% Upside Potential - DirectorsTalk Interviews
TD Cowen Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $554 - Moomoo
Praxis Precision Medicines Q1 2026: Loss Narrows 12.1% to -$3.20/Share - AlphaStreet
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $537 - Moomoo
Jefferies raises Praxis Precision Medicines stock price target on pipeline catalysts - Investing.com UK
Wolfe Research initiates coverage of Praxis Precision Medicines (PRAX) with outperform recommendation - MSN
Jefferies raises Praxis Precision Medicines stock price target on pipeline catalysts By Investing.com - Investing.com South Africa
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Praxis Precision Medicines Inc 주식 (PRAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
0.29%
0.81%
자본화:
|
볼륨(24시간):